Sarepta gene therapy for Duchenne misses main goal of key study
Bio Pharma Dive
OCTOBER 30, 2023
Yet Sarepta said it still plans to ask the FDA to expand regulatory clearance of Elevidys, which was granted an accelerated approval by the FDA in June.
Mon.Oct 30, 2023
296 
FDA warns of infection risks from over-the-counter eye drops
Pharmaceutical Technology
OCTOBER 30, 2023
The US FDA has issued a warning against the use of 26 over-the-counter eye drop products due to potential eye infection risks.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Why prospective real-world studies hold so much promise for clinical research
Bio Pharma Dive
OCTOBER 30, 2023
PrwS studies can reach beyond the limitations of today’s RWE studies and expand the role of RWD across the entire drug development cycle.
‘Grave Consequences’: Scientists Warn of Extreme Bias in Brain Aging Research
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2023
The risk of Alzheimer’s disease and depression differs significantly between male and female bodies, and yet the vast majority of research on the human brain does not reflect that. Instead, male anatomy is too often considered ‘the norm’ against which all other human brains are measured.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Abingworth raises $356M to invest in late-stage drug development
Bio Pharma Dive
OCTOBER 30, 2023
The venture firm has supported a number of approved medicines with its co-development strategy, including Pfizer’s Besponsa and Apellis’ Empaveli.
EMA dismisses thyroid cancer link with anti-obesity GLP-1 receptor agonists
Pharmaceutical Technology
OCTOBER 30, 2023
An EMA safety panel concluded that available evidence does not prove that GLP-1 receptor agonists cause thyroid cancer.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
AI skills can increase worker salary as much as 40%, says study
Pharmaceutical Technology
OCTOBER 30, 2023
A new study published by the Oxford Internet Institute has found that AI skills and knowledge can increase a worker’s salary as much as 40%.
Novartis bet on kidney disease drug yields positive study data
Bio Pharma Dive
OCTOBER 30, 2023
The pharma paid more than $3 billion this summer to acquire Chinook Therapeutics and a therapy that just met its goal in a Phase 3 trial.
Coherus and Junshi’s PD-1 inhibitor approved for nasopharyngeal carcinoma
Pharmaceutical Technology
OCTOBER 30, 2023
A Loqtorzi/chemotherapy combination has been approved as a first-line therapy in adults with metastatic or recurrent locally advanced NPC.
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
Bio Pharma Dive
OCTOBER 30, 2023
MapLight Therapeutics’ Series C round saw participation from existing backers as well as new ones like Novo Holdings, 5AM Ventures and Cowen Healthcare Investments.
Intas licenses Helnius’s antibody for marketing in Europe and India
Pharmaceutical Technology
OCTOBER 30, 2023
Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.
Sanofi invests in MeiraGTx and its gene-regulating technology
Bio Pharma Dive
OCTOBER 30, 2023
In addition to Sanofi’s investment, the biotech signaled it’s weighing deals with “multiple” other companies that have expressed interest in its work.
UK allocates £100m for AI-powered new drug development
Pharmaceutical Technology
OCTOBER 30, 2023
The UK government has allocated £100m investment in AI-powered drug development for previously incurable conditions
UPDATED: Pfizer plans to shutter New Jersey site, discloses layoffs amid $3.5B cost-cutting drive
Fierce Pharma
OCTOBER 30, 2023
Editor's note: This story has been updated with a comment from Pfizer. An earlier version of the story stated that nearly 800 jobs would be affected. | After plunging COVID revenues prompted Pfizer to embark on a cost-cutting crusade, more details about the company's savings efforts are coming into focus.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Merck partners with Hengrui in deal worth up to $1.48bn
Pharmaceutical Technology
OCTOBER 30, 2023
Merck has gained worldwide rights outside of China for PARP1 trapping inhibitor HRS-1167 and ADC drug SHR-A1904.
How To Effectively Engage With Indonesian Authorities For Medical Device Approval
Pharma Mirror
OCTOBER 30, 2023
Indonesia, being the fourth most populous country in the world, presents a significant market opportunity for medical device manufacturers. The Indonesia medical device registration process is a necessary pathway for any foreign manufacturer looking to supply their products in this burgeoning market. The growth potential is immense due to the increasing healthcare expenditure and growing awareness about advanced medical technologies among the population.
Signal: UK Biobank raises £32m in funding via public-private partnership
Pharmaceutical Technology
OCTOBER 30, 2023
Eric Schmidt and Ken Griffin have led the UK Biobank funding round, donating a government-matched $10m each that may be used for AI.
NIHR data reveals commercial study set up times reduce by a third
Pharma Times
OCTOBER 30, 2023
Over 600 commercial studies have been reviewed in the past 12 months - News - PharmaTimes
Rishi Sunak addresses existential AI threats ahead of UK safety summit
Pharmaceutical Technology
OCTOBER 30, 2023
UK Prime Minister Rishi Sunak has vowed to tackle fears surrounding AI in a speech ahead of the world’s first AI safety summit next week.
Clinical trial disparities and how to build a more inclusive future
pharmaphorum
OCTOBER 30, 2023
Clinical trial disparities and how to build a more inclusive future Mike.
Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug
Pharmaceutical Technology
OCTOBER 30, 2023
ALX-001 is currently being studied in a Phase Ib safety study and designs for a Phase II ALX-001 proof-of-concept study are underway.
Eli Lilly, Redwire head to space to explore next frontier of drug development
Fierce Pharma
OCTOBER 30, 2023
After Bristol Myers Squibb’s space odyssey earlier this year, another pharmaceutical major is pushing drug development to the fringes of Earth’s gravitational pull. | Eli Lilly is entering the orbit of Redwire Corporation to test the latter company's in-space drug manufacturing platform. The technology will be sent to the International Space Station aboard a SpaceX mission set to launch sometime after Nov. 5.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
EMA validates BMS’ Opdivo application for bladder cancer
Pharmaceutical Technology
OCTOBER 30, 2023
If approved, the combination with chemotherapy would be the first of its kind to receive European authorisation for 1L urothelial cancer.
Understanding primary sclerosing cholangitis symptoms
Antidote
OCTOBER 30, 2023
Primary sclerosing cholangitis (PSC) is an autoimmune disease that mainly targets bile ducts in the liver. PSC is a rare condition, impacting about 1 in 10,000 people worldwide , and it is diagnosed twice as frequently in men as it is in women.
Will mobile visits help the clinical trials industry meet its diversity goals?
Pharmaceutical Technology
OCTOBER 30, 2023
Lowering barriers to participation could boost the diversity of patients in clinical trials. We analyze gender, race and ethnicity data to understand the differences that mobile visits from a certified mobile research nurse can make.
Coherus rejects 'heavily discounted' pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nod
Fierce Pharma
OCTOBER 30, 2023
Market watchers have been waiting keenly to see whether a cheap China-made cancer drug could disrupt the multibillion-dollar U.S. PD-1 cancer immunotherapy market. | Market watchers have been waiting keenly to see whether a cheap China-made cancer drug could disrupt the multibillion-dollar U.S. PD-1 cancer immunotherapy market. But the first player with a chance to follow that path has opted not to.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
EMA accepts ImmunoGen’s MAA for ovarian cancer therapy
Pharmaceutical Technology
OCTOBER 30, 2023
The EMA accepted ImmunoGen MAA for mirvetuximab soravtansine (ELAHERE) to treat patients with primary peritoneal cancer.
Sarepta's Elevidys fails on primary endpoint, but executives see path to wider DMD approval anyway
Fierce Pharma
OCTOBER 30, 2023
After Sarepta overcame several regulatory hurdles to finally win | After Sarepta overcame several regulatory hurdles to finally win FDA approval for its DMD gene therapy Elevidys, the company now faces the prospect of more FDA scrutiny because a pivotal study on the drug has failed on the primary endpoint.
AbbVie posts drop in Q3 2023 attributable net earnings
Pharmaceutical Technology
OCTOBER 30, 2023
AbbVie has posted net earnings attributable to the company of $17.78bn in Q3 2023 versus $39.49bn in the same quarter of 2022.
Amgen, Regeneron and AbbVie join Lilly and Novo Nordisk in posting largest Q3 market-cap gains: report
Fierce Pharma
OCTOBER 30, 2023
As sales of their GLP-1 diabetes and obesity drugs have surged, Eli Lilly and Novo Nordisk have become the most valuable biopharma companies in the United States and Europe, respectively. That didn | It was no surprise that GLP-1 drugmakers Eli Lilly and Novo Nordisk saw market-cap gains of 16.1% and 13.9% in the third quarter. But much less expected were the market-cap rallies of Amgen (22.1%), Regeneron (14.9%) and AbbVie (13.1%), according to figures compiled by GlobalData.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content